Sanofi Stock Probability Of Bankruptcy
| SNYNF Stock | USD 92.70 0.58 0.63% |
Sanofi |
Sanofi Company chance of financial distress Analysis
Sanofi's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Sanofi Probability Of Bankruptcy | Less than 9% |
Most of Sanofi's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sanofi is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Sanofi probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Sanofi odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Sanofi financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Sanofi has a Probability Of Bankruptcy of 9.0%. This is 79.21% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The probability of bankruptcy for all United States stocks is 77.4% higher than that of the company.
Sanofi Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sanofi could also be used in its relative valuation, which is a method of valuing Sanofi by comparing valuation metrics of similar companies.Sanofi is currently under evaluation in probability of bankruptcy category among related companies.
Sanofi Fundamentals
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 135.37 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 11.23 % | |||
| Shares Owned By Institutions | 46.69 % | |||
| Price To Earning | 7.73 X | |||
| Price To Book | 1.60 X | |||
| Price To Sales | 2.73 X | |||
| Revenue | 45.39 B | |||
| Gross Profit | 31.69 B | |||
| EBITDA | 10.76 B | |||
| Net Income | 6.72 B | |||
| Cash And Equivalents | 6.9 B | |||
| Cash Per Share | 5.51 X | |||
| Total Debt | 14.86 B | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 58.33 X | |||
| Cash Flow From Operations | 10.52 B | |||
| Earnings Per Share | 5.77 X | |||
| Price To Earnings To Growth | 1.63 X | |||
| Target Price | 123.28 | |||
| Number Of Employees | 58 | |||
| Beta | 0.41 | |||
| Market Capitalization | 120.25 B | |||
| Total Asset | 124.58 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.83 % | |||
| Net Asset | 124.58 B | |||
| Last Dividend Paid | 3.56 |
About Sanofi Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Sanofi Pink Sheet analysis
When running Sanofi's price analysis, check to measure Sanofi's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi is operating at the current time. Most of Sanofi's value examination focuses on studying past and present price action to predict the probability of Sanofi's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi's price. Additionally, you may evaluate how the addition of Sanofi to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |